Anvesha Singh1, Daniel C S Chan2, John P Greenwood3, Dana K Dawson4, Piotr Sonecki5, Kai Hogrefe6, Damian J Kelly7, Vijay Dhakshinamurthy8, Chim C Lang9, Jeffery P Khoo10, David Sprigings11, Richard P Steeds12, Ruiqi Zhang13, Ian Ford13, Michael Jerosch-Herold14, Jing Yang15, Zhuyin Li15, Leong L Ng2, Gerry P McCann2. 1. Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, United Kingdom. Electronic address: as707@le.ac.uk. 2. Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, United Kingdom. 3. Multidisciplinary Cardiovascular Research Centre & The Division of Biomedical Imaging, Leeds Institute of Cardiovascular & Metabolic Medicine, Leeds University, Leeds, United Kingdom. 4. Cardiovascular Medicine Research Unit, School of Medicine and Dentistry, University of Aberdeen, Foresterhill, Aberdeen, United Kingdom. 5. BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom. 6. Cardiology Department, Kettering General Hospital Foundation Trust, Kettering, United Kingdom. 7. Cardiology Department, Royal Derby Hospital, Derby, United Kingdom. 8. Cardiology Department, University Hospital, Coventry, United Kingdom. 9. Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, Dundee, United Kingdom. 10. Cardiology Department, Glenfield Hospital, Leicester, United Kingdom. 11. Northampton General Hospital, Cliftonville, Northampton, United Kingdom. 12. Institute for Cardiovascular Sciences, University of Birmingham, Department of Cardiology, Queen Elizabeth Hospital, Birmingham, United Kingdom. 13. Roberston Centre for Bisotatistics, University of Glasgow, Glasgow, United Kingdom. 14. Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 15. Bristol-Myers Squibb Company, Princeton, New Jersey.
Abstract
OBJECTIVES: The aim of this study was to establish sex differences in remodeling and outcome in aortic stenosis (AS) and their associations with biomarkers of myocardial fibrosis. BACKGROUND: The remodeling response and timing of symptoms is highly variable in AS, and sex plays an important role. METHODS: A total of 174 patients (133 men, mean age 66.2 ± 13.3 years) with asymptomatic moderate to severe AS underwent comprehensive stress cardiac magnetic resonance imaging, transthoracic echocardiography, and biomarker analysis (matrix metalloproteinase [MMP]-2, -3, -7, -8, and -9; tissue inhibitor matrix metalloproteinases-1 and -4; syndecan-1 and -4; and N-terminal pro-B-type natriuretic peptide), and were followed up at 6-month intervals. A primary endpoint was a composite of typical AS symptoms necessitating referral for aortic valve replacement, cardiovascular death, or major adverse cardiovascular events. RESULTS: For a similar severity of AS, male patients demonstrated higher indexed left ventricular (LV) volumes and mass, more concentric remodeling (higher LV mass/volume), a trend to more late gadolinium enhancement (present in 51.1% men vs. 34.1% women; p = 0.057), and higher extracellular volume index than female patients (13.27 [interquartile range (IQR): 11.5 to 17.0] vs. 11.53 [IQR: 10.5 to 13.5] ml/m2, p = 0.017), with worse systolic and diastolic function and higher MMP-3 and syndecan-4 levels, whereas female patients had higher septal E/e'. Male sex was independently associated with indexed LV mass (β = 13.32 [IQR: 9.59 to 17.05]; p < 0.001). During median follow-up of 374 (IQR: 351 to 498) days, a primary outcome, driven by spontaneous symptom onset, occurred in 21.8% of male and 43.9% of female patients (relative risk: 0.50 [95% confidence interval: 0.31 to 0.80]; p = 0.004). Measures of AS severity were associated with the primary outcome in both sexes, whereas N-terminal pro-B-type natriuretic peptide, MMP-3, and mass/volume were only associated in men. CONCLUSIONS: In AS, women tolerate pressure overload with less concentric remodeling and myocardial fibrosis but are more likely to develop symptoms. This may be related to higher wall stress and filling pressures in women.
OBJECTIVES: The aim of this study was to establish sex differences in remodeling and outcome in aortic stenosis (AS) and their associations with biomarkers of myocardial fibrosis. BACKGROUND: The remodeling response and timing of symptoms is highly variable in AS, and sex plays an important role. METHODS: A total of 174 patients (133 men, mean age 66.2 ± 13.3 years) with asymptomatic moderate to severe AS underwent comprehensive stress cardiac magnetic resonance imaging, transthoracic echocardiography, and biomarker analysis (matrix metalloproteinase [MMP]-2, -3, -7, -8, and -9; tissue inhibitor matrix metalloproteinases-1 and -4; syndecan-1 and -4; and N-terminal pro-B-type natriuretic peptide), and were followed up at 6-month intervals. A primary endpoint was a composite of typical AS symptoms necessitating referral for aortic valve replacement, cardiovascular death, or major adverse cardiovascular events. RESULTS: For a similar severity of AS, male patients demonstrated higher indexed left ventricular (LV) volumes and mass, more concentric remodeling (higher LV mass/volume), a trend to more late gadolinium enhancement (present in 51.1% men vs. 34.1% women; p = 0.057), and higher extracellular volume index than female patients (13.27 [interquartile range (IQR): 11.5 to 17.0] vs. 11.53 [IQR: 10.5 to 13.5] ml/m2, p = 0.017), with worse systolic and diastolic function and higher MMP-3 and syndecan-4 levels, whereas female patients had higher septal E/e'. Male sex was independently associated with indexed LV mass (β = 13.32 [IQR: 9.59 to 17.05]; p < 0.001). During median follow-up of 374 (IQR: 351 to 498) days, a primary outcome, driven by spontaneous symptom onset, occurred in 21.8% of male and 43.9% of female patients (relative risk: 0.50 [95% confidence interval: 0.31 to 0.80]; p = 0.004). Measures of AS severity were associated with the primary outcome in both sexes, whereas N-terminal pro-B-type natriuretic peptide, MMP-3, and mass/volume were only associated in men. CONCLUSIONS: In AS, women tolerate pressure overload with less concentric remodeling and myocardial fibrosis but are more likely to develop symptoms. This may be related to higher wall stress and filling pressures in women.
Authors: Vanessa Dela Justina; Jéssica S G Miguez; Fernanda Priviero; Jennifer C Sullivan; Fernanda R Giachini; R Clinton Webb Journal: Front Aging Date: 2021-09-10
Authors: Anish N Bhuva; Thomas A Treibel; Antonio De Marvao; Carlo Biffi; Timothy J W Dawes; Georgia Doumou; Wenjia Bai; Kush Patel; Redha Boubertakh; Daniel Rueckert; Declan P O'Regan; Alun D Hughes; James C Moon; Charlotte H Manisty Journal: Eur Heart J Cardiovasc Imaging Date: 2020-04-01 Impact factor: 6.875
Authors: Kang H Zheng; Benoit J Arsenault; Yannick Kaiser; Kay-Tee Khaw; Nicholas J Wareham; Erik S G Stroes; S Matthijs Boekholdt Journal: J Am Heart Assoc Date: 2019-08-13 Impact factor: 5.501
Authors: Gaurav S Gulsin; Prathap Kanagala; Daniel C S Chan; Adrian S H Cheng; Lavanya Athithan; Matthew P M Graham-Brown; Anvesha Singh; Jing Yang; Zhuyin Li; Kamlesh Khunti; Melanie J Davies; Jayanth R Arnold; Iain B Squire; Leong L Ng; Gerry P McCann Journal: Ther Adv Endocrinol Metab Date: 2019-07-05 Impact factor: 3.565
Authors: Prathap Kanagala; Jayanth R Arnold; Anvesha Singh; Daniel C S Chan; Adrian S H Cheng; Jamal N Khan; Gaurav S Gulsin; Jing Yang; Lei Zhao; Pankaj Gupta; Iain B Squire; Leong L Ng; Gerry P McCann Journal: PLoS One Date: 2020-04-29 Impact factor: 3.240
Authors: Anvesha Singh; Tarique Al Musa; Thomas A Treibel; Vassiliou S Vassiliou; Gabriella Captur; Calvin Chin; Laura E Dobson; Silvia Pica; Margaret Loudon; Tamir Malley; Marzia Rigolli; James Robert John Foley; Petra Bijsterveld; Graham R Law; Marc Richard Dweck; Saul G Myerson; Sanjay K Prasad; James C Moon; John P Greenwood; Gerry P McCann Journal: Heart Date: 2019-08-29 Impact factor: 5.994
Authors: Volha I Summerhill; Donato Moschetta; Alexander N Orekhov; Paolo Poggio; Veronika A Myasoedova Journal: Int J Mol Sci Date: 2020-08-06 Impact factor: 5.923